Cargando…

TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription

Comparatively less toxic and more tolerated, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommendable for advanced non-small-cell lung cancer (NSCLC) patients with EGFR-sensitive mutations. Some EGFR wild-type patients with specific biomarkers also show a response to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Weiwei, Xu, Wei, Li, Yan, Jiang, Wei, Li, Yue, Huang, Qiqing, Chen, Bo, Wu, Shuangshuang, Wang, Yu, Song, Weiwei, Zhao, Weihong, Wu, Jianqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433914/ https://www.ncbi.nlm.nih.gov/pubmed/30911072 http://dx.doi.org/10.1038/s41419-019-1519-z

Ejemplares similares

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
por: Xu, Wei, et al.
Publicado: (2015)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

DNA damage induced by human CD40 ligand mutant promotes senescence and induces demethylation of GATA4 in lung cancer
por: Li, Yue, et al.
Publicado: (2018)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
por: Li, Jerry, et al.
Publicado: (2021)

Microglial-stimulation of glioma invasion involves the EGFR ligand amphiregulin
por: Coniglio, Salvatore J., et al.
Publicado: (2021)

Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
por: Han, Shu-Yan, et al.
Publicado: (2014)

The Amphiregulin/EGFR axis has limited contribution in controlling autoimmune diabetes
por: Raugh, Arielle, et al.
Publicado: (2023)

The amphiregulin/EGFR axis has limited contribution in controlling autoimmune diabetes
por: Raugh, Arielle, et al.
Publicado: (2023)

The role of transcriptional coactivator TAZ in gliomas
por: Li, Weijie, et al.
Publicado: (2016)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
por: Chen, Yun-Ju, et al.
Publicado: (2011)

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas
por: Xu, Wei, et al.
Publicado: (2021)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Oncogenic signaling in amphiregulin and EGFR‐expressing PTEN‐null human breast cancer
por: Kappler, Christiana S., et al.
Publicado: (2014)

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
por: Gong, Hao, et al.
Publicado: (2020)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Amphiregulin Regulates Phagocytosis-Induced Cell Death in Monocytes via EGFR and Matrix Metalloproteinases
por: Platen, Christopher, et al.
Publicado: (2018)

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway
por: Taverna, Simona, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis
por: Huang, Qiqing, et al.
Publicado: (2020)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Interleukin-19 Aggravates Pulmonary Fibrosis via Activating Fibroblast through TGF-β/Smad Pathway
por: Wang, Yu, et al.
Publicado: (2022)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
por: Jiang, Yuhong, et al.
Publicado: (2021)

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
por: Oliveras-Ferraros, C, et al.
Publicado: (2012)

Docosahexaenoic Acid Serving As Sensitizing Agents And Gefitinib Resistance Revertants In EGFR Targeting Treatment
por: Ding, Xuansheng, et al.
Publicado: (2019)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP
por: Wei, Yunyan, et al.
Publicado: (2016)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

Abnormal amphiregulin expression correlates with gastric cancer prognosis
por: Wang, Bing, et al.
Publicado: (2016)

Amphiregulin Regulates Melanocytic Senescence
por: Pommer, Michaela, et al.
Publicado: (2021)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
por: Alfieri, Roberta R, et al.
Publicado: (2011)

Amphiregulin Antibody and Reduction of Axial Elongation in Experimental Myopia
por: Jiang, Wen Jun, et al.
Publicado: (2017)

Prognostic Value of Survival of MicroRNAs Signatures in Non-small Cell Lung Cancer
por: Chen, Bo, et al.
Publicado: (2019)

Amphiregulin Regulates Phagocytosis-Induced Cell Death in Monocytes via EGFR and the Bcl-2 Protein Family
por: Platen, Christopher, et al.
Publicado: (2019)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j80bf5qbrgpfak3vrjgvcc0m20